Primary immunodeficiency diseases represent a group of more than 300 rare chronic disorders where part of the body’s immune system is missing or does not function properly.
Cuvitru, injected once a month, can infuse up to 60 milliliters per site per hour, which results in fewer injection sites and shorter treatment durations for patients.
“In the clinical study, primary immunodeficiency patients tolerated Cuvitru favorably despite the use of higher infusion site volumes and more rapid infusion rates than have been routine in the past,” said Richard Wasserman, MD, PhD, medical director of pediatric allergy and immunology at Dallas-based Medical City Children’s Hospital.
Dublin-based Shire will launch Cuvitru in the U.S. in the next few weeks.
More articles on supply chain:
FDA skeptic of Pfizer’s request to remove warning from drug label
Global Logistic Properties buys US distribution center portfolio for $1.1B
Regional Health wins supply chain performance award
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
